IBRX · NASDAQ · Biotechnology

ImmunityBio (IBRX)

Commercializes ANKTIVA while developing cytokine, NK-cell, and vaccine immunotherapies for cancer.

$8.70
vs last close−0.59 (−6.30%)
  1. Why Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report?

    Zacks Investment ResearchMarket move